Asian Journal of Research in Pharmaceutical Sciences

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Formulation of Clindamycine hydrochloride Vaginal Suppository Containing Lacto Bacillus Spores


Affiliations
1 MJRP college of heath Care and Allied Sciences, MJRP university, Jaipur, India
2 Sharad Pawar College of Pharmacy, Nagpur, India
     

   Subscribe/Renew Journal


The present research and study is directed to Anti-microbial and lactic acid bacillus combination in a comprising pharmaceutical acceptable carrier and the methods for treating fungal, bacterial, protozoal and yeast infection. Some of the most common pathogens associates with invasive fungal infections are the opportunistic yeast, such as Candida spp. and Asppergillus spp. thousands of Candida spp cells can be present in an individual, primarily in the gastrointestinal tract, as a harmless commensal organism. However, Candida spp., such as C.albicans, cause oppotunistics fungal infections. Infections can be localized such as a vaginal infection or an oral infection, both of which cause a considerable degree of discomfort. The objective of this study was to develop a vaginal suppository containing lacti acid bacillus spores. Further the present research study provided the combination of anti infective drug Clindamycine Hydrochloride with micro organism lactic acid bacillus spores in a pharmaceutical formulation as suppository.

Keywords

Vaginosis, Lactic acid Bacillus Spores, Clindamycine Hydrochloride, Formulation, Viability Stability.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Penn RL. Gynecological and obstetrical infections. In: Reese RE, Gordon Douglas Jr. R, 2nd ed. A practical approach to infectious diseases. Boston: Little, Brown and Company; 1986. p.385-421.

  • Thadepalli H, Gorbach SL, Keith L. Anaerobic infections of the female genital tract; bacteriologic and therapeutic aspects. Am-J Obstet Gynecol 1973;117:1034-40.

  • Ledger WJ. Micro-organisms that cause infection. In: Ledger WJ, ed. Infections in the female. 2nd ed. Philadelphia: Lea & Febiger;1986.p.9-34.

  • Ledger WJ. Antimicrobial agents. In: Ledger WJ,2nd ed. Infections in the female. Philadelphia: Lea & Febiger;1986.p.95- 126.

  • Bleker OP, Folkertsma K, Dirks-Go SIS. Diagnostic procedures in vaginitis. Eur J Obstet Gynecol Reprod Biol 1989;31:10-11.

  • Bleker OP, Folkertsma K, Dirks-Go SIS. Diagnostic procedures in vaginitis. Eur J Obstet Gynecol Reprod Biol 1989;31:179-83.

  • McFarland LV. Beneficial microbes: health or hazard? Eur J Gastroenterol Hepatol 2000;12:1069-1071.

  • Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000;15:489-493.

  • Larsen B. Vaginal flora in health and disease. Clin Obstet Gynecol 1993; 36:107–121.

  • Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis. 1990; 12:856–872.

  • Hiller SL. The vaginal microbial ecosystem and resistance to HIV. AIDS Res Hum Retroviruses 1998;14(suppl 1):17–21.

  • Boris S, Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000;2:543– 546.

  • Sobel JD. Vaginitis. N Engl J Med 1997;337:1896–1903.

  • McGregor JA, French JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv 2000;55(suppl 5):1–19.

  • Sweet RL. Role of bacterial vaginosis in pelvic inflammatory diseases. J Infect Dis 1995; 20(suppl 2):271–275. 16. Sooper DE. Bacterial vaginosis and postoperative infections. Am J Obstet Gynecol 1993; 169:467–469.

  • Van de Wijgert, J.H.H.M., Mason, P.R. and Gwanzura, L. et al. Intravaginal practices, vaginal £ora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J. Infect. Dis. 2000;181,587-594.

  • Chaim, W., Mazor, M. and Leiberman, J.R. The relationship between bacterial vaginosis and preterm birth. Arch. Gynecol. Obstet.1997;259: 51-58.

  • Reid G. and Bruce, A.W. Selection of Lactobacillus strains for urogenital probiotic applications. J. Infect. Dis. 2001;183(Suppl.1),S77- 80.

  • Reid, G., Bruce, A.W. and Taylor, M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol. Ther.1995; 23: 32-45.

  • Eller M.G., Smith R.B. and Phillips J.P., Absorption kinetics of topical clindamycin preparations. Biopharm. Drug Disposition 1989;10 :505-512.

  • Feldman S, Careccia RE, Barham KL, Hancox J . "Diagnosis and treatment of acne". Am Fam Physician 2004;69 (9):2123–30

  • Cunliffe WJ, Holland KT, Bojar R, Levy SF "A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris". Clin Ther 2002;24(7):1117– 33.

  • Schlünzen F, Zarivach R, Harms J, et al. . "Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria". Nature 2001;413(6858):814–21.

  • Parry M.F. and Rha C.K., Pseudomembranous colitis caused by topical clindamycin phosphate. Arc. Dermatol.1986;122:583-594.

  • Sanae K, and Nattha K, Formulation and Evaluation of Vaginal Suppositories Containing Lactobacillus, World Academy of Science, Engineering and Technology 2009;(31):630-633.

  • Formulation development and release studies of indomethacin suppositories, ML sah, TR Saini, short communications, Ind. J. pharm. Sciences 2008;70(4):498-501.

  • Naikwade Sonali R, Kulkarni Pratibha P, Jathar Shripad R, Bajaj Amrita N. DARU 2008; 16 (3):119-127.


Abstract Views: 485

PDF Views: 65




  • Formulation of Clindamycine hydrochloride Vaginal Suppository Containing Lacto Bacillus Spores

Abstract Views: 485  |  PDF Views: 65

Authors

S.C. Shivhare
MJRP college of heath Care and Allied Sciences, MJRP university, Jaipur, India
U.D. Shivhare
Sharad Pawar College of Pharmacy, Nagpur, India
Preeti Srivastav
MJRP college of heath Care and Allied Sciences, MJRP university, Jaipur, India
K.G. Malviya
MJRP college of heath Care and Allied Sciences, MJRP university, Jaipur, India

Abstract


The present research and study is directed to Anti-microbial and lactic acid bacillus combination in a comprising pharmaceutical acceptable carrier and the methods for treating fungal, bacterial, protozoal and yeast infection. Some of the most common pathogens associates with invasive fungal infections are the opportunistic yeast, such as Candida spp. and Asppergillus spp. thousands of Candida spp cells can be present in an individual, primarily in the gastrointestinal tract, as a harmless commensal organism. However, Candida spp., such as C.albicans, cause oppotunistics fungal infections. Infections can be localized such as a vaginal infection or an oral infection, both of which cause a considerable degree of discomfort. The objective of this study was to develop a vaginal suppository containing lacti acid bacillus spores. Further the present research study provided the combination of anti infective drug Clindamycine Hydrochloride with micro organism lactic acid bacillus spores in a pharmaceutical formulation as suppository.

Keywords


Vaginosis, Lactic acid Bacillus Spores, Clindamycine Hydrochloride, Formulation, Viability Stability.

References